General Information of the Drug (ID: M6APDG03403)
Name
CDP-1050
Synonyms
Ryanodine receptor modulators (heart failure), Cordex; Ryanodine receptor modulators (heart failure), Duke University; Ryanodine receptor modulators (heart failure), Duska Therapeutics
    Click to Show/Hide
Status
Discontinued in Phase 1
TTD Drug ID
D0C3HS
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Ryanodine receptor 1 (RYR1)
Methyltransferase-like 16 (METTL16)
In total 1 mechanisms lead to this potential drug response
Response Summary Ryanodine receptor 1 (RYR1) is a therapeutic target for CDP-1050. The Methyltransferase-like 16 (METTL16) has potential in affecting the response of CDP-1050 through regulating the expression of Ryanodine receptor 1 (RYR1). [1], [2]
References
Ref 1 Human METTL16 is a N(6)-methyladenosine (m(6)A) methyltransferase that targets pre-mRNAs and various non-coding RNAs. EMBO Rep. 2017 Nov;18(11):2004-2014. doi: 10.15252/embr.201744940. Epub 2017 Oct 19.
Ref 2 The Ryanodine Receptor Stabilizer S44121 / Arm036 Improves Peripheral and Respiratory Muscle Function in a Mouse Model of Heart Failure. Circulation. 2014; 130: A13726.